These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 15565413)

  • 1. Secondary resistance to imatinib mesylate in a patient with unresectable duodenal GIST without mutations in exons 9, 11, 13, or 17 of the c-kit protooncogene.
    Yamaguchi M; Matsumoto T; Tate G; Higuchi T
    J Gastroenterol; 2004 Sep; 39(9):904-5. PubMed ID: 15565413
    [No Abstract]   [Full Text] [Related]  

  • 2. [Molecular and histologic characteristics of secondary imatinib-resistant gastrointestinal stromal tumors].
    Zheng S; Jia J; Pan YL; Tao DY; Lu HS
    Zhonghua Bing Li Xue Za Zhi; 2013 Jan; 42(1):42-3. PubMed ID: 23611272
    [No Abstract]   [Full Text] [Related]  

  • 3. Correlation of imatinib resistance with the mutational status of KIT and PDGFRA genes in gastrointestinal stromal tumors: a meta-analysis.
    Lee JH; Kim Y; Choi JW; Kim YS
    J Gastrointestin Liver Dis; 2013 Dec; 22(4):413-8. PubMed ID: 24369323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of imatinib mesylate in a patient with a metastatic gastrointestinal stromal tumor with a c-kit mutation in exon 11.
    Kubota K; Katayama A; Takeshita Y; Nozaki K; Ueda T; Imamura K; Hiki N; Nomura S; Kaminishi M; Mafune K
    Dig Dis Sci; 2007 Jul; 52(7):1725-9. PubMed ID: 17546507
    [No Abstract]   [Full Text] [Related]  

  • 5. [KIT mutation analysis in pathological diagnosis and target-therapy of gastrointestinal stromal tumors: an update].
    Chen LR
    Zhonghua Bing Li Xue Za Zhi; 2007 Jul; 36(7):440-3. PubMed ID: 17845754
    [No Abstract]   [Full Text] [Related]  

  • 6. Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations.
    Wardelmann E; Thomas N; Merkelbach-Bruse S; Pauls K; Speidel N; Büttner R; Bihl H; Leutner CC; Heinicke T; Hohenberger P
    Lancet Oncol; 2005 Apr; 6(4):249-51. PubMed ID: 15811621
    [No Abstract]   [Full Text] [Related]  

  • 7. [Clinical and molecular characterization of gastrointestinal stromal tumors (GIST)].
    Mac K; Wójcik M
    Postepy Hig Med Dosw (Online); 2007 Jun; 62():272-81. PubMed ID: 18542042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imatinib in the management of multiple gastrointestinal stromal tumors associated with a germline KIT K642E mutation.
    Graham J; Debiec-Rychter M; Corless CL; Reid R; Davidson R; White JD
    Arch Pathol Lab Med; 2007 Sep; 131(9):1393-6. PubMed ID: 17824795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Consensus on the medical treatment of gastrointestinal stromal tumors].
    Zhonghua Zhong Liu Za Zhi; 2007 Nov; 29(11):875-7. PubMed ID: 18396652
    [No Abstract]   [Full Text] [Related]  

  • 10. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation.
    Antonescu CR; Besmer P; Guo T; Arkun K; Hom G; Koryotowski B; Leversha MA; Jeffrey PD; Desantis D; Singer S; Brennan MF; Maki RG; DeMatteo RP
    Clin Cancer Res; 2005 Jun; 11(11):4182-90. PubMed ID: 15930355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GIST under imatinib therapy.
    Sciot R; Debiec-Rychter M
    Semin Diagn Pathol; 2006 May; 23(2):84-90. PubMed ID: 17193821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors.
    Desai J; Shankar S; Heinrich MC; Fletcher JA; Fletcher CD; Manola J; Morgan JA; Corless CL; George S; Tuncali K; Silverman SG; Van den Abbeele AD; van Sonnenberg E; Demetri GD
    Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5398-405. PubMed ID: 17875769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic changes in advanced gastrointestinal stromal tumor (GIST) patients during imatinib mesylate treatment.
    Yeh CN; Chen TW; Liu FY; Jan YY; Chen MF
    Langenbecks Arch Surg; 2006 Nov; 391(6):615-21. PubMed ID: 17024483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New strategies for treating GIST when imatinib fails.
    Boyar MS; Taub RN
    Cancer Invest; 2007 Aug; 25(5):328-35. PubMed ID: 17661208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of KIT in the management of patients with gastrointestinal stromal tumors.
    Hornick JL; Fletcher CD
    Hum Pathol; 2007 May; 38(5):679-87. PubMed ID: 17437861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to imatinib mesylate depends on the presence of the V559A-mutated KIT oncogene.
    Terheyden P; Houben R; Pajouh P; Thorns C; Zillikens D; Becker JC
    J Invest Dermatol; 2010 Jan; 130(1):314-6. PubMed ID: 19812602
    [No Abstract]   [Full Text] [Related]  

  • 17. Recurrent gastrointestinal stromal tumor (GIST) of the stomach associated with a novel c-kit mutation after imatinib treatment.
    Koyama T; Nimura H; Kobayashi K; Marushima H; Odaira H; Kashimura H; Mitsumori N; Yanaga K
    Gastric Cancer; 2006; 9(3):235-9. PubMed ID: 16952044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secondary c-kit mutation in a recurrent gastrointestinal stromal tumor under long-term treatment with imatinib mesylate: report of a case.
    Utsunomiya T; Okamoto M; Yano S; Kameyama T; Matsuyama A; Kuma S; Yamamoto M; Fujiwara M; Ishida T
    Surg Today; 2008; 38(1):65-7. PubMed ID: 18085368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Chinese consensus in diagnosis and treatment of gastrointestinal stromal tumor].
    Chinese Diagnosis and Treatment Experts Group for Gastrointestinal Stromal Tumors
    Zhonghua Bing Li Xue Za Zhi; 2009 Oct; 38(10):697-702. PubMed ID: 20078976
    [No Abstract]   [Full Text] [Related]  

  • 20. C-KIT mutations were closely associated with the response to Imatinib in Chinese advanced gastrointestinal stromal tumor patients.
    Gao J; Dang Y; Sun N; Li J; Shen L
    Med Oncol; 2012 Dec; 29(5):3039-45. PubMed ID: 22815156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.